{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:39:37Z","timestamp":1791635977562,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Robust and well-defined data collection is important when using electronic patient-reported outcome measures (ePROMs) in clinical studies. Questions have been raised as to whether older age may be a barrier to data collection due to patients\u2019 unfamiliarity with electronic devices. Older adults may also have underlying health conditions that affect their ability to fill out patient-reported outcome measures (PROMs) on electronic devices. The aim of this observational, qualitative research study was to evaluate the usability of electronic PROMs (ePROMs) on a tablet and smartphone in older participants with and without bullous pemphigoid (BP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Older people with and without BP were recruited in the US and France. They participated in 60-min in-person interviews, with moderators observing their completion of various tasks, including ePROMs, using a tablet and smartphone. Participants were scored on ease of task completion using a scale from 1 to 5.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 12 participants were recruited (\u226565\u00a0years old; six each with and without BP [all participants without BP were \u226575\u00a0years old]). Most participants (83%) could easily and confidently perform most assigned tasks on both the tablet and smartphone. Although select tasks required assistance, all participants were eventually able to complete all tasks. Overall, ePROM usability did not correlate with age, sex, country, or disease state. Feedback on the general usability of both electronic devices was largely positive, and most participants (n\u2009=\u200911; 92%) were willing to use them. Participants were generally pleased with the training modules offered on both devices, describing the training as sufficient, straightforward, and helpful. In total, 25 usability issues were identified, which fell into three categories: incomplete instructions, unclear language, and insufficient technical\/visual design. Participants provided feedback on how to enhance device usability.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results suggest that older people can confidently use a tablet or smartphone for ePROM completion, particularly with appropriate training. ePROMs should be designed with the needs of the target patient population in mind. These results can be leveraged to improve clinical data recording, optimize device usability, and enhance the user experience for older people and those with functional or physical limitations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s41687-024-00821-w","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T12:17:01Z","timestamp":1734524221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Assessing usability of electronic patient-reported outcome measures in older people with and without a rare dermatologic disorder"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3360-9651","authenticated-orcid":false,"given":"Calvin N.","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"K\u00fcndig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lila","family":"Bahadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Roat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline P.","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Moll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"issue":"6","key":"821_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1177\/2168479015609102","volume":"49","author":"S Fleming","year":"2015","unstructured":"Fleming S, Barsdorf AI, Howry C, O\u2019Gorman H, Coons SJ (2015) Optimizing electronic capture of clinical outcome assessment data in clinical trials: the case of patient-reported endpoints. Ther Innov Regul Sci 49(6):797\u2013804. https:\/\/doi.org\/10.1177\/2168479015609102","journal-title":"Ther Innov Regul Sci"},{"key":"821_CR2","unstructured":"United States Food and Drug Administration (2018) Methods to identify what is important to patients & select, develop or modify fit-for-purpose clinical outcomes assessments. https:\/\/www.fda.gov\/media\/116276\/download. Accessed 22 Apr 2024"},{"issue":"1","key":"821_CR3","doi-asserted-by":"publisher","first-page":"e15588","DOI":"10.2196\/15588","volume":"3","author":"J Meirte","year":"2020","unstructured":"Meirte J, Hellemans N, Anthonissen M, et al (2020) Benefits and disadvantages of electronic patient-reported outcome measures: systematic review. JMIR Perioper Med 3(1):e15588. https:\/\/doi.org\/10.2196\/15588","journal-title":"JMIR Perioper Med"},{"issue":"8","key":"821_CR4","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.jval.2023.02.011","volume":"26","author":"S Hudgens","year":"2023","unstructured":"Hudgens S, Kern S, Barsdorf AI, et al (2023) Best practice recommendations for electronic patient-reported outcome dataset structure and standardization to support drug development. Value Health 26(8):1242\u20131248. https:\/\/doi.org\/10.1016\/j.jval.2023.02.011","journal-title":"Value Health"},{"issue":"2","key":"821_CR5","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.2196\/cancer.6996","volume":"3","author":"AD Hartkopf","year":"2017","unstructured":"Hartkopf AD, Graf J, Simoes E, et al (2017) Electronic-based patient-reported outcomes: willingness, needs, and barriers in adjuvant and metastatic breast cancer patients. JMIR Cancer 3(2):e11. https:\/\/doi.org\/10.2196\/cancer.6996","journal-title":"JMIR Cancer"},{"issue":"5","key":"821_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jval.2023.01.001","volume":"26","author":"P O\u2019Donohoe","year":"2023","unstructured":"O\u2019Donohoe P, Reasner DS, Kovacs SM, et al (2023) Updated recommendations on evidence needed to support measurement comparability among modes of data collection for patient-reported outcome measures: a good practices report of an ISPOR task force. Value Health 26(5):623\u2013633. https:\/\/doi.org\/10.1016\/j.jval.2023.01.001","journal-title":"Value Health"},{"key":"821_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12913-015-0698-2","volume":"15","author":"C Bahler","year":"2015","unstructured":"Bahler C, Huber CA, Brungger B, Reich O (2015) Multimorbidity, health care utilization and costs in an elderly community-dwelling population: a claims data based observational study. BMC Health Serv Res 15:23. https:\/\/doi.org\/10.1186\/s12913-015-0698-2","journal-title":"BMC Health Serv Res"},{"key":"821_CR8","unstructured":"World Health Organization (2022) Ageing and health: 2022 key facts. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health. Accessed 22 Apr 2024"},{"issue":"12","key":"821_CR9","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1111\/jdv.16401","volume":"34","author":"HM Passlov","year":"2020","unstructured":"Passlov HM, Ponten A, Bjork J, et al (2020) Hand strength and dexterity in individuals with hand eczema. J Eur Acad Dermatol Venereol 34(12):2856\u20132862. https:\/\/doi.org\/10.1111\/jdv.16401","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"821_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/2397198320965382","volume":"6","author":"G Moroncini","year":"2021","unstructured":"Moroncini G, Brunzini A, Papetti A, et al (2021) Development of the optimal touchscreen interface for patients with scleroderma. J Scleroderma Relat Disord 6(2):170\u2013177. https:\/\/doi.org\/10.1177\/2397198320965382","journal-title":"J Scleroderma Relat Disord"},{"issue":"1","key":"821_CR11","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1186\/s12889-021-11623-w","volume":"21","author":"J Wilson","year":"2021","unstructured":"Wilson J, Heinsch M, Betts D, Booth D, Kay-Lambkin F (2021) Barriers and facilitators to the use of e-health by older adults: a scoping review. BMC Public Health 21(1):1556. https:\/\/doi.org\/10.1186\/s12889-021-11623-w","journal-title":"BMC Public Health"},{"key":"821_CR12","doi-asserted-by":"publisher","first-page":"1159351","DOI":"10.3389\/fimmu.2023.1159351","volume":"14","author":"M Rosi-Schumacher","year":"2023","unstructured":"Rosi-Schumacher M, Baker J, Waris J, Seiffert-Sinha K, Sinha AA (2023) Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid. Front Immunol 14:1159351. https:\/\/doi.org\/10.3389\/fimmu.2023.1159351","journal-title":"Front Immunol"},{"issue":"1","key":"821_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/bjd.19022","volume":"184","author":"MSM Persson","year":"2021","unstructured":"Persson MSM, Harman KE, Vinogradova Y, et al (2021) Incidence, prevalence and mortality of bullous pemphigoid in England 1998-2017: a population-based cohort study. Br J Dermatol 184(1):68\u201377. https:\/\/doi.org\/10.1111\/bjd.19022","journal-title":"Br J Dermatol"},{"key":"821_CR14","doi-asserted-by":"publisher","unstructured":"Moro F, Fania L, Sinagra JLM, Salemme A, Di Zenzo G (2020) Bullous pemphigoid: trigger and predisposing factors. Biomolecules 10(10). https:\/\/doi.org\/10.3390\/biom10101432","DOI":"10.3390\/biom10101432"},{"issue":"6","key":"821_CR15","doi-asserted-by":"publisher","first-page":"938","DOI":"10.5114\/ada.2020.102111","volume":"37","author":"A Kalinska-Bienias","year":"2020","unstructured":"Kalinska-Bienias A, Kowalczyk E, Jagielski P, et al (2020) Clinical characteristics of pruritus in patients with bullous pemphigoid: a preliminary questionnaire-based study. Postepy Dermatol Alergol 37(6):938\u2013942. https:\/\/doi.org\/10.5114\/ada.2020.102111","journal-title":"Postepy Dermatol Alergol"},{"key":"821_CR16","unstructured":"AstraZeneca (2023) NCT04612790 a study to investigate the use of benralizumab in patients with bullous pemphigoid (FJORD). https:\/\/clinicaltrials.gov\/study\/NCT04612790. Accessed 5 June 2024"},{"key":"821_CR17","first-page":"206","volume-title":"Proceedings of the ACM INTERACT \u201893 and CHI \u201893 Conference, May 1993, Amsterdam, the Netherlands","author":"J Nielsen","year":"1993","unstructured":"Nielsen J, Landauer TK (1993) A mathematical model of the finding of usability problems. In: Proceedings of the ACM INTERACT \u201893 and CHI \u201893 Conference, May 1993, Amsterdam, the Netherlands, pp 206\u2013213"},{"key":"821_CR18","unstructured":"Pew Research Centre (2024) Fact sheets: tech adoption trends; mobile fact sheet. https:\/\/www.pewresearch.org\/internet\/fact-sheet\/mobile\/. Accessed 12 Mar 2024"},{"key":"821_CR19","volume-title":"Insee Focus, Janvier 2022, No. 259. 94 % des 15\u201329 ans ont un smartphone en 2021 - Insee Focus - 259","author":"S Leglaye","year":"2021","unstructured":"Leglaye S, Nougaret A, Viard-Guillot L (2021) 94% des 15\u201329 ans ont un smartphone en 2021. In: Insee Focus, Janvier 2022, No. 259. 94 % des 15\u201329 ans ont un smartphone en 2021 - Insee Focus - 259. Accessed 22 Apr 2024"},{"issue":"3","key":"821_CR20","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/life13030660","volume":"13","author":"MB Green","year":"2023","unstructured":"Green MB, Duker JS (2023) Adverse ocular effects of systemic medications. Life (Basel) 13(3):660. https:\/\/doi.org\/10.3390\/life13030660","journal-title":"Life (Basel)"},{"issue":"11","key":"821_CR21","doi-asserted-by":"publisher","first-page":"S480","DOI":"10.1016\/j.jval.2023.09.2603","volume":"26","author":"B McDowell","year":"2023","unstructured":"McDowell B, Muehlhausen W, Doll HA, et al (2023) Accessibility vs standardization: a study of electronic implementation of patient-reported outcomes measures with vision-impaired participants. Value Health 26(11):S480. https:\/\/doi.org\/10.1016\/j.jval.2023.09.2603","journal-title":"Value Health"},{"key":"821_CR22","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41591-024-02827-9","volume":"30","author":"OL Aiyegbusi","year":"2024","unstructured":"Aiyegbusi OL, Rivera SC, Roydhouse J, et al (2024) Recommendations to address respondent burden associated with patient-reported outcome assessment. Nat Med 30:650\u2013659. https:\/\/doi.org\/10.1038\/s41591-024-02827-9","journal-title":"Nat Med"},{"issue":"1","key":"821_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jval.2023.10.007","volume":"27","author":"FD Mowlem","year":"2024","unstructured":"Mowlem FD, Elash CA, Dumais KM, et al (2024) Best practices for the electronic implementation and migration of patient-reported outcome measures. Value Health 27(1):79\u201394. https:\/\/doi.org\/10.1016\/j.jval.2023.10.007","journal-title":"Value Health"},{"issue":"22","key":"821_CR24","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1200\/JCO.23.0215","volume":"42","author":"M Cancel","year":"2024","unstructured":"Cancel M, Sauger C, Biogeau J, et al (2024) FASTOCH: feasibility of electronic patient-reported outcomes in older patients with cancer\u2014a multicenter prospective study. J Clin Oncol 42(22):2713\u20132722. https:\/\/doi.org\/10.1200\/JCO.23.0215","journal-title":"J Clin Oncol"},{"issue":"4","key":"821_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2217\/cer-2019-0155","volume":"9","author":"K Garner","year":"2020","unstructured":"Garner K, Byrom B (2020) Attitudes of older people\/seniors to completion of electronic patient-reported outcome measures and use of mobile applications in clinical trials: results of a qualitative research study. J Comp Eff Res 9(4):307\u2013315. https:\/\/doi.org\/10.2217\/cer-2019-0155","journal-title":"J Comp Eff Res"},{"key":"821_CR26","unstructured":"House of Lords Science and Technology Select Committee (2021) Ageing: science, technology and healthy living. Ageing: Science, Technology and Healthy Living (parliament.uk). Accessed 12 Mar 2024"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00821-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-024-00821-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00821-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T13:02:27Z","timestamp":1734526947000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-024-00821-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["821"],"URL":"https:\/\/doi.org\/10.1186\/s41687-024-00821-w","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"6 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practice and applicable regulatory requirements. Independent institutional review for this study was provided by WCG (WIRB-Copernicus Group) IRB (Tracking Number: 20230164), and all participants consented to participate in this research via signed informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No patient-identifiable data have been presented. Informed consent stipulated that if the results of this study are published, no patient will be identified.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CNH, LB, and AK are employees of AstraZeneca and may own stock\/stock options. KR, KK, RB, and CPG are employees of IQVIA, which received funding from AstraZeneca to conduct this study. TM is an employee of Clario, which received funding from AstraZeneca to (1) create the electronic build for the study and (2) supply the devices.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}